Fulgent (FLGT): Price-to-Projected Revenue Ratio

fulgentgenetics.com (FLGT) - corporate logo

Fulgent Genetics, Inc. (FLGT) is recognized as a high-tech leader in precision diagnostics, valued by clinics for its accuracy. The estimated forward P/S objectively captures the market valuation of the business, where 2.10 serves as the final level marker. The company seeks dominance via its cloud IT platform, while a stable defensive moat is provided by its transition into the digital oncology diagnostics segment and services for the pharmaceutical industry.

fulgentgenetics.com - FLGT Projected Price to Revenue (period 07/04/2022 - 11/13/2026)

Fulgent - analytical breakdowns and key metrics (FLGT)

- stock price and consensus target price:
Stock Quotes Fulgent Genetics|FLGT - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Fulgent|FLGT - Total Company Value
- book value of equity indicators:
Book Value per Share Fulgent Genetics|FLGT - Book Value of Business|Market Capitalization to Book Value Ratio fulgentgenetics.com|FLGT - Company Assets
- business debt structure and liquidity details:
Debt to Equity Fulgent Genetics, Inc.|FLGT - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Fulgent Genetics, Inc.|FLGT - Company Cumulative Indebtedness|Debt to Book Value Fulgent|FLGT - Company Long-Term Loans and Borrowings|Company Short-Term Debts Fulgent Genetics|Quick Ratio fulgentgenetics.com
- financial results and valuation multiples details:
FLGT - Company Net Income|Expected Profit Fulgent Genetics, Inc.|FLGT - Price to Earnings Multiple|Forward P/E Multiple Fulgent Corp|FLGT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Fulgent|FLGT - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Fulgent Genetics|FLGT - Net earnings per share for the last four quarters|Quarterly EPS earnings growth fulgentgenetics.com|FLGT - Net earnings per share growth this year|Net earnings per share growth forecast for next year Fulgent Genetics, Inc.
- revenue and sales proceeds data:
FLGT - Company Gross Revenue|Company Future Sales Volume Fulgent Genetics|FLGT - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Fulgent
General company analysis:Fulgent Genetics (FLGT)
Original product of fulgentgenetics.com

This metric serves as a stress-testing tool for assets when determining the fair value of shares. It reflects the ratio of current market capitalization to projected sales volume, measuring the premium the market is willing to pay for future revenue growth. By analyzing the forward price-to-sales valuation, an investor can track the dynamics of market expectations. For Fulgent Genetics, Inc. (FLGT), this is critical, as the scaling of cloud diagnostics and bioinformatics directly impacts the pace of revenue expansion.

Key competitors

Agilent - Forward Price-to-Revenue Multiple|Forward P/S Multiple Quest Diagnostics Inc. DGX|ILMN - Price-to-Projected Revenue Ratio|EXAS: Price-to-Projected Revenue Ratio|RVTY: Forward P/S Multiple|Projected Price to Revenue bio-rad.com BIO|NNNN (Anbio) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Sotera Health Corp SHC|Price-to-Projected Revenue Ratio QuidelOrtho Corp (QDEL)|OPKO Health Corp. - Market Cap to Projected Revenue|CareDx, Inc - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio MRVI (maravai.com)|LAB: Forward Price-to-Revenue Multiple|Forward Price to Sales CTKB (Cytek Biosciences Inc)|OSUR: Forward P/S Multiple|Projected Price to Revenue Exagen XGN|MDXH (MDxHealth SA) - Forward P/S Multiple|Market Cap to Future Revenue Ratio luciddx.com LUCD|Price-to-Projected Revenue Ratio Prenetics Global (PRE)|imdxinc.com - Market Cap to Projected Revenue|Forward P/S Multiple TRIB (Trinity Biotech)|ProPhase Labs Corp (PRPH) - Market Cap to Future Revenue Ratio|AIMD: Forward Price-to-Revenue Multiple|codiagnostics.com - Price to Expected Revenue Ratio|HSCS: Forward P/S Multiple|BMRA - Market Cap to Expected Sales Ratio|CDIO (Cardio Diagnostics Holdings Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Onconetix Corporation (ONCO)|Price-to-Projected Revenue Ratio Virax Biolabs Group (VRAX)|Market Cap to Expected Sales Ratio bluejaydx.com|Aspira Women's Health Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales AXDX|centogene.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio Enzo Biochem, Inc. ENZ|fresh2.co (FRES) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue GENE|ME (23andMe) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Psychemedics Corp. (PMD)